Bliss GVS Pharma

Why is Bliss GVS Pharma Ltd falling/rising?

As of 05-Aug, Bliss GVS Pharma Ltd's stock price is rising to 505.05, up 3.29% due to strong financial performance, increased investor participation, and positive market sentiment. The stock has outperformed its sector and is trading above key moving averages, indicating robust investor confidence.

As of 05-Aug, Bliss GVS Pharma Ltd's stock price is rising, currently at 505.05, reflecting a change of 16.1 (3.29%) upward. This increase can be attributed to several factors. The stock has outperformed the sector by 2.34% today and has shown a consecutive gain over the last two days, accumulating a total return of 7.34% during this period. Additionally, the stock opened with a gain of 3.08% today and reached an intraday high of Rs 513, marking a rise of 4.92%.<BR><BR>The stock's performance is further supported by its strong position relative to moving averages, as it is trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. There has also been a notable increase in investor participation, with delivery volume rising by 33.17% compared to the 5-day average, indicating heightened interest among investors.<BR><BR>Financially, Bliss GVS Pharma is net-debt free, and recent positive results show a significant growth in profit after tax (PAT) of 128.8% for the quarter ending March 26. The company also boasts a high return on capital employed (ROCE) of 16.80% and a very low debt-equity ratio of 0.02 times. Furthermore, institutional investors have increased their stake by 2.05% in the previous quarter, now holding 17.54% of the company, which reflects confidence from more sophisticated market participants.<BR><BR>Overall, the combination of strong financial performance, positive market sentiment, and increased investor participation has contributed to the rising stock price of Bliss GVS Pharma Ltd.

Which are the latest news on Bliss GVS Pharma?

How big is Bliss GVS Pharma?

As of 10th June, Bliss GVS Pharma Ltd has a market capitalization of 4,403.00 Cr and reported net sales of 927.11 Cr and net profit of 129.14 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Bliss GVS Pharma Ltd has a market capitalization of 4,403.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 927.11 Cr, while the sum of Net Profit for the same period is 129.14 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 1,050.38 Cr, and Total Assets amount to 1,300.84 Cr.

Who are in the management team of Bliss GVS Pharma?

The management team of Bliss GVS Pharma includes Vibha G Sharma and Shruti Vishal Rao as Whole-time Directors, Subramanian R Vaidya as Chairman & Independent Director, and Gagan Harsh Sharma as Managing Director, among others. Key members also include Aditi Bhatt (Company Secretary) and several Non-Executive & Independent Directors.

The management team of Bliss GVS Pharma includes the following key members:<BR><BR>1. **Vibha G Sharma** - Whole-time Director<BR>2. **Shruti Vishal Rao** - Whole-time Director<BR>3. **Subramanian R Vaidya** - Chairman & Independent Director<BR>4. **Santosh Parab** - Non-Executive & Independent Director<BR>5. **Aditi Bhatt** - Company Secretary & Compliance Officer<BR>6. **Shilpa Bhatia** - Non-Executive & Independent Director<BR>7. **Gagan Harsh Sharma** - Managing Director<BR><BR>If you need more specific information about any of these individuals or their roles, feel free to ask!

Who are the peers of the Bliss GVS Pharma?

Peers of Bliss GVS Pharma include SPARC, FDC, Aarti Pharma, Senores Pharma, Innova Captab, Orchid Pharma, Guj. Themis Bio, Advanced Enzyme, IOL Chemicals, and Zota Health Care. Bliss GVS Pharma has a 1-year return of 185.09%, significantly higher than its peers, with Senores Pharma leading at 117.67% and Aarti Pharma at -31.47%.

Peers: The peers of Bliss GVS Pharma are SPARC, FDC, Aarti Pharma, Senores Pharma, Innova Captab, Orchid Pharma, Guj. Themis Bio, Advanced Enzyme, IOL Chemicals, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Senores Pharma and Guj. Themis Bio, while Average management risk is found at SPARC, FDC, Aarti Pharma, Bliss GVS Pharma, Advanced Enzyme, and IOL Chemicals. Below Average management risk is noted at Orchid Pharma. In terms of Growth, Excellent growth is seen at SPARC and Senores Pharma, while Below Average growth is reported for FDC, Aarti Pharma, Innova Captab, Bliss GVS Pharma, Orchid Pharma, and Zota Health Care, and the rest. Good growth is noted at Guj. Themis Bio. For Capital Structure, Excellent capital structure is observed at FDC, Aarti Pharma, Innova Captab, Bliss GVS Pharma, Guj. Themis Bio, and IOL Chemicals, while Average capital structure is found at SPARC and Advanced Enzyme, and Below Average at Orchid Pharma and Zota Health Care.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Senores Pharma at 117.67%, while the lowest is Aarti Pharma at -31.47%. Bliss GVS Pharma's own 1-year return is 185.09%, which is significantly higher than both extremes. Additionally, Orchid Pharma and Zota Health Care have negative six-month returns.

What does Bliss GVS Pharma do?

Bliss GVS Pharma Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, originally founded in 1984. As of March 2026, it reported net sales of 257 Cr and a net profit of 36 Cr, with a market cap of INR 4,403 Cr.

Overview:<BR>Bliss GVS Pharma Ltd is a company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap.<BR><BR>History:<BR>The company was originally incorporated in 1984 as Bliss Chemicals & Pharmaceuticals India Private Limited. It later converted to a Public Limited Company and changed its name to Bliss Chemicals & Pharmaceuticals India Limited, eventually becoming Bliss GVS Pharma Limited on May 12, 2006. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 257 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 36 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 4,403 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 34.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.24%<BR>- Debt Equity: -0.12<BR>- Return on Equity: 10.95%<BR>- Price to Book: 3.74<BR><BR>Contact Details:<BR>- Address: 102 Hyde Park Sakivihar Road, Andheri East Mumbai Maharashtra : 400072<BR>- Tel: 91-22-42160000<BR>- Email: info@blissgvs.com<BR>- Website: http://www.blissgvs.com

Should I buy, sell or hold Bliss GVS Pharma Ltd?

Are Bliss GVS Pharma Ltd latest results good or bad?

Bliss GVS Pharma Ltd's latest results show strong quarterly performance with record revenue and profit growth; however, concerns about long-term growth and capital efficiency suggest potential challenges ahead. Investors should weigh the impressive short-term results against the company's slower historical growth rates and underlying structural issues.

Bliss GVS Pharma Ltd's latest results present a mixed picture. On one hand, the company achieved record revenue of ₹256.99 crores for Q4 FY26, marking a significant 29.80% year-on-year growth and a 17.75% sequential increase. Additionally, net profit surged to ₹35.58 crores, reflecting a remarkable 128.96% increase compared to the same quarter last year. The operating margin also improved to 17.29%, up from 10.65% a year ago, indicating strong operational performance.<BR><BR>However, despite these impressive quarterly results, there are underlying concerns regarding the company's long-term growth trajectory. The five-year sales compound annual growth rate (CAGR) stands at just 8.97%, and the EBIT CAGR is even lower at 3.85%. This suggests structural challenges that could hinder sustainable growth. Furthermore, the company's return on equity (ROE) and return on capital employed (ROCE) ratios are below the levels typically expected from quality pharmaceutical companies, indicating potential inefficiencies in capital deployment.<BR><BR>Additionally, the recent volatility in quarterly performance raises questions about the sustainability of the recent momentum. While the stock has delivered outstanding returns of 137.65% over the past year, this performance appears increasingly disconnected from the underlying fundamentals.<BR><BR>In summary, while Bliss GVS Pharma's latest quarterly results are strong, the long-term growth outlook presents significant concerns that investors should carefully consider.

When is the next results date for Bliss GVS Pharma Ltd?

The next results date for Bliss GVS Pharma Ltd is 12 May 2026.

The next results date for Bliss GVS Pharma Ltd is scheduled for 12 May 2026.

Has Bliss GVS Pharma Ltd declared dividend?

Yes, Bliss GVS Pharma Ltd has declared a dividend of 50% (0.5 per share) with an ex-date of February 18, 2026. The company has shown strong total returns across various periods, indicating a positive financial performance.

Bliss GVS Pharma Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 0.5<BR>- Ex-date: 18 Feb 26<BR><BR>Dividend Yield: 0.24%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 37.64%, the dividend return was 0.30%, leading to a total return of 37.94%.<BR><BR>Over the past 6 months, the price return stood at 23.66%, with a dividend return of 0.29%, resulting in a total return of 23.95%.<BR><BR>For the 1-year period, Bliss GVS Pharma Ltd experienced a price return of 49.44%, a dividend return of 0.79%, culminating in a total return of 50.23%.<BR><BR>In the 2-year timeframe, the company achieved a price return of 84.19%, with a dividend return of 1.20%, leading to a total return of 85.39%.<BR><BR>Over 3 years, the price return was 189.4%, accompanied by a dividend return of 2.58%, resulting in a total return of 191.98%.<BR><BR>For the 4-year period, the price return was 131.93%, with a dividend return of 3.25%, leading to a total return of 135.18%.<BR><BR>In the last 5 years, the price return was 17.3%, with a dividend return of 1.77%, resulting in a total return of 19.07%.<BR><BR>Overall, Bliss GVS Pharma Ltd has declared a substantial dividend and demonstrated strong total returns across various periods, indicating a positive financial performance. The combination of price appreciation and dividend returns reflects a healthy investment opportunity.

Is Bliss GVS Pharma overvalued or undervalued?

As of December 4, 2025, Bliss GVS Pharma is fairly valued with a PE ratio of 16.35, outperforming the Sensex recently, while compared to peers, Sun Pharma is expensive at a PE of 37.78, and Aurobindo Pharma is also fairly valued at a PE of 20.77.

As of 4 December 2025, the valuation grade for Bliss GVS Pharma has moved from attractive to fair. The company is currently fairly valued based on its financial metrics, with a PE ratio of 16.35, an EV to EBITDA of 13.26, and a PEG ratio of 0.92. In comparison to its peers, Sun Pharma is considered expensive with a PE ratio of 37.78, while Aurobindo Pharma is also fair with a PE ratio of 20.77.<BR><BR>Despite the recent downgrade in valuation grade, Bliss GVS Pharma has shown resilience, outperforming the Sensex over the past week and month, with returns of 2.32% and 10.20%, respectively. Overall, the company appears to be fairly valued in the current market context, reflecting its competitive position within the pharmaceuticals and biotechnology industry.

Is Bliss GVS Pharma technically bullish or bearish?

As of December 4, 2025, Bliss GVS Pharma shows a strong bullish trend supported by positive MACD and Bollinger Bands indicators, despite some mildly bearish signals from KST and Dow Theory.

As of 4 December 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend on both time frames. Daily moving averages confirm a bullish stance as well. However, the KST shows a mildly bearish signal on the weekly and monthly, and Dow Theory indicates a mildly bullish trend on the weekly with no trend on the monthly. Overall, the bullish indicators outweigh the bearish signals, suggesting a strong bullish sentiment in the current market for Bliss GVS Pharma.

How has been the historical performance of Bliss GVS Pharma?

Bliss GVS Pharma has experienced steady growth in net sales and profits, with net sales increasing from INR 747.45 crore in March 2022 to INR 809.73 crore in March 2025. However, rising expenditures and liabilities pose challenges despite improvements in profit before tax and consolidated net profit.

Answer:<BR>The historical performance of Bliss GVS Pharma shows a mixed trend in financial metrics over the years.<BR><BR>Breakdown:<BR>Bliss GVS Pharma's net sales have seen a steady increase from INR 747.45 crore in March 2022 to INR 809.73 crore in March 2025, reflecting a positive growth trajectory. The total operating income also rose correspondingly, reaching INR 809.73 crore in March 2025. However, the total expenditure, excluding depreciation, increased from INR 619.62 crore in March 2024 to INR 683.04 crore in March 2025, impacting the operating profit, which decreased from INR 150.62 crore to INR 126.69 crore in the same period. Despite this, the profit before tax improved from INR 116.87 crore to INR 125.64 crore, leading to a profit after tax of INR 90.26 crore in March 2025, up from INR 81.58 crore in March 2024. The consolidated net profit also increased to INR 84.30 crore in March 2025 from INR 75.45 crore in March 2024. On the balance sheet, total assets grew from INR 1,211.59 crore in March 2024 to INR 1,300.84 crore in March 2025, while total liabilities also increased, but at a slower pace, from INR 1,211.59 crore to INR 1,300.84 crore. Cash flow from operating activities showed a slight increase to INR 105 crore in March 2025, compared to INR 102 crore in March 2024, indicating stable operational cash generation. Overall, while Bliss GVS Pharma has shown growth in sales and profits, the rising costs and liabilities present challenges that the company will need to address moving forward.

Who are the top shareholders of the Bliss GVS Pharma?

The top shareholders of Bliss GVS Pharma include Narsimha Shibroor Kamath with 30.78%, Arian Investment Limited at 8.58%, and individual investors holding 32.63%. Additionally, 42 foreign institutional investors hold 13.18%, with no pledged promoter holdings.

The top shareholders of Bliss GVS Pharma include Narsimha Shibroor Kamath, who holds the highest promoter stake at 30.78%. The highest public shareholder is Arian Investment Limited, with a holding of 8.58%. Additionally, individual investors collectively hold 32.63% of the shares. The company also has 42 foreign institutional investors (FIIs) with a combined holding of 13.18%, while mutual funds hold a negligible amount through two schemes. Notably, there are no pledged promoter holdings.

What is the bonus history of the Bliss GVS Pharma?

Bliss GVS Pharma announced a bonus issue in a ratio of 3:5, with an ex-date of September 26, 2008, and a record date of September 30, 2008. Shareholders received 3 additional shares for every 5 shares held.

Bliss GVS Pharma has a recorded bonus history where they announced a bonus issue in a ratio of 3:5. The ex-date for this bonus was on September 26, 2008, and the record date was September 30, 2008. This means that for every 5 shares held, shareholders received 3 additional shares as a bonus. If you have any more questions about the company or its financial activities, feel free to ask!